Diclofenac

CHEMBL139 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
296.1 g/mol
LogP
4.4
Phase
4

A widely used NSAID that inhibits both COX-1 and COX-2 enzymes to reduce prostaglandin synthesis, providing anti-inflammatory, analgesic, and antipyretic effects for conditions including arthritis, acute pain, and dysmenorrhea. It is available in oral, topical, and injectable formulations.

分子量

296.1000 g/mol

LogP

4.40

TPSA

49.30 Ų

リピンスキーの五則

適合

治療領域

作用機序

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl

InChI

InChI=1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)

Molecular Formula

C14H11Cl2NO2

HBD / HBA

2 / 3

回転可能結合数

4

重原子数

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A widely used NSAID that inhibits both COX-1 and COX-2 enzymes to reduce prostaglandin synthesis, providing anti-inflammatory, analgesic, and antipyretic effects for conditions including arthritis, acute pain, and dysmenorrhea. It is available in oral, topical, and injectable formulations.

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Yes, Diclofenac is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL139. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3033. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.